Jaguar Health Reports Financial Obligations and Equity Sales

Ticker: JAGX · Form: 8-K · Filed: 2025-05-15T00:00:00.000Z

Sentiment: neutral

Topics: material-definitive-agreement, financial-obligation, equity-sale

TL;DR

Jaguar Health took on new debt and sold more stock on May 13th.

AI Summary

On May 13, 2025, Jaguar Health, Inc. entered into a material definitive agreement, likely related to its financial obligations. The company also reported on its results of operations and financial condition. Additionally, Jaguar Health disclosed the creation of a direct financial obligation and unregistered sales of equity securities.

Why It Matters

This filing indicates potential new debt or financing for Jaguar Health, alongside equity issuances, which could impact its financial structure and shareholder value.

Risk Assessment

Risk Level: medium — The filing details new financial obligations and unregistered equity sales, which can introduce financial risk and dilution.

Key Players & Entities

FAQ

What type of material definitive agreement did Jaguar Health, Inc. enter into?

The filing states that Jaguar Health, Inc. entered into a material definitive agreement on May 13, 2025, but the specific details of the agreement are not provided in this excerpt.

What are the key aspects of Jaguar Health's results of operations and financial condition reported?

The filing indicates that Jaguar Health reported on its results of operations and financial condition, but the specific details are not included in this excerpt.

What kind of direct financial obligation was created by Jaguar Health?

The filing mentions the creation of a direct financial obligation by Jaguar Health, Inc., but the nature and terms of this obligation are not specified in this excerpt.

Were there any unregistered sales of equity securities by Jaguar Health?

Yes, the filing indicates that there were unregistered sales of equity securities by Jaguar Health, Inc.

What is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported in this 8-K filing is May 13, 2025.

From the Filing

0001193125-25-120763.txt : 20250515 0001193125-25-120763.hdr.sgml : 20250515 20250515160032 ACCESSION NUMBER: 0001193125-25-120763 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 19 CONFORMED PERIOD OF REPORT: 20250513 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250515 DATE AS OF CHANGE: 20250515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Jaguar Health, Inc. CENTRAL INDEX KEY: 0001585608 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36714 FILM NUMBER: 25952324 BUSINESS ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 415-371-8300 MAIL ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 FORMER COMPANY: FORMER CONFORMED NAME: Jaguar Animal Health, Inc. DATE OF NAME CHANGE: 20130830 8-K 1 d63848d8k.htm 8-K 8-K false 0001585608 --12-31 0001585608 2025-05-13 2025-05-13     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025     Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter)       Delaware   001-36714   46-2956775 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)   200 Pine Street     Suite 400     San Francisco , California     94104 (Address of Principal Executive Offices)     (Zip Code) Registrant’s Telephone Number, Including Area Code: (415) 371-8300 (Former Name or Former Address, if Changed Since Last Report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, Par Value $0.0001 Per Share   JAGX   The Nasdaq Stock Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 1.01 Entry into a Material Definitive Agreement. Common Stock Exchange Transaction As previously disclosed, on October 8, 2020, Jaguar Health, Inc. (the “Comp

View on Read The Filing